Revvity Inc (RVTY)

Health Services • Health Care

Stock AI

News & Reports

July 20, 2026 Revvity Inc. Releases 2026 Impact Report: Advancing Transparency and Sustainability Revvity Inc. released its 2026 Impact Report, showcasing key achievements in sustainability, including reduced emissions and waste management success. The report emphasizes the company's commitment to transparency, responsible governance, and workforce development initiatives.

July 08, 2026 Revvity Inc. Set to Release Q2 2026 Financial Results Revvity Inc. is set to announce its Q2 2026 financial results on August 4. The earnings call will feature key executives discussing the company's performance and future direction in the healthcare sector.

July 01, 2026 Revvity Inc. Enhances Scientific Research Capabilities with Anthropic Claude Integration Revvity Inc. has integrated its Signals Software with Anthropic's Claude to enhance AI capabilities in scientific research. This integration allows researchers to access reliable data and utilize natural language queries for improved efficiency in research and healthcare solutions.

June 22, 2026 Revvity Inc. Unveils Signals AI: A Game-Changer for Scientific R&D Revvity Inc. has launched Signals AI, an innovative framework to streamline scientific R&D processes and help researchers derive actionable insights from vast data. This tool allows scientists to interact with their data using natural language, enhancing efficiency and decision-making in research.

May 05, 2026 Revvity Inc. Reports Strong Q1 2026 Financial Results Amid Strategic Divestiture Revvity, Inc. announced strong Q1 2026 financial results with a revenue increase of 6.9% and a strategic divestiture of its Immunodiagnostics business in China. The company’s solid performance reflects growth in both revenue and earnings, setting a positive outlook for the year ahead.

April 30, 2026 Revvity Inc. Declares Quarterly Dividend Amidst Strong Financial Performance Revvity, Inc. has declared a quarterly dividend of $0.07 per share, reflecting its strong financial performance with $2.9 billion in revenue for 2025. The company emphasizes its commitment to healthcare innovation and has established a significant global presence as a member of the S&P 500.

April 10, 2026 Revvity Inc. Prepares for Q1 Earnings Call Amidst Healthcare Innovations Revvity Inc. is set to hold its Q1 earnings call on May 5, 2026, offering insights into its financial results and strategic direction. The call, led by CEO Prahlad Singh, underscores the company's commitment to innovation in healthcare. Stakeholders can access the live webcast on the company’s website.

April 09, 2026 Revvity Inc. Launches Signals BioDesign to Transform Biologic Research Revvity Inc. has launched Signals BioDesign™, a cloud-native platform designed to transform biologics research by integrating essential cloning methodologies. With features supporting high-throughput cloning and real-time collaboration, it aims to accelerate therapeutic development. Revvity will debut this innovative solution at the Bio-IT World Conference & Expo.

February 24, 2026 Revvity Inc. Reports Steady Growth Amidst Economic Challenges in 2025 Revvity Inc. reported a 4% revenue growth in 2025, achieving $2.86 billion in total revenue. The company's Diagnostics and Life Sciences segments were key drivers of this growth, despite facing challenges in gross margins and operating income. Revvity remains focused on innovation and strategic initiatives for future growth.

February 17, 2026 Revvity Inc. Set to Showcase Strategic Vision at Key Investor Conferences Revvity, Inc. will participate in key investor conferences in March 2026, sharing insights on its strategic initiatives. Presentations will be accessible via live webcasts and replays for broader engagement. The company is committed to transforming healthcare through innovation and advanced technologies.

February 05, 2026 Revvity Inc. Launches Groundbreaking Discovery Platforms at SLAS2026 Revvity Inc. launched new high-impact discovery platforms at SLAS2026, including the Opera Phenix OptIQ™ and EnVision Nexus™ One, aimed at revolutionizing drug discovery workflows. These innovations enhance laboratory automation and data accuracy, positioning Revvity as a leader in the life sciences sector.

February 02, 2026 Revvity Inc. Reports Strong Financial Results for Fourth Quarter and Full Year 2025 Revvity Inc. announced its fourth quarter and full year 2025 financial results, showcasing revenue growth but challenges in profitability margins. The company projects stable revenue growth for 2026, highlighting confidence in its strategic positioning.

January 26, 2026 Revvity Inc. Declares Quarterly Dividend: A Strategic Move for Shareholders Revvity, Inc. has declared a quarterly dividend of $0.07 per share, set to be paid on May 8, 2026, signaling its dedication to shareholder returns and financial stability. The company continues to innovate in health sciences, with a robust revenue exceeding $2.7 billion and a global presence.

January 12, 2026 Revvity Inc. Prepares for Earnings Call with Positive Financial Update Revvity Inc. is set to announce its earnings for Q4 and full year 2025 on February 2, 2026, with preliminary results indicating positive revenue growth. CEO Prahlad Singh will also present at the J.P. Morgan Healthcare Conference, highlighting the company's resilience and strategic direction.

January 09, 2026 Revvity Inc. Partners with Eli Lilly to Enhance AI Drug Discovery Revvity Inc. has partnered with Eli Lilly to integrate advanced AI predictive models into its Signals platform, enhancing drug discovery capabilities. This collaboration aims to improve research efficiency and foster innovation in the biotech industry.

December 18, 2025 Revvity Inc. Set to Present at J.P. Morgan Healthcare Conference 2026 Revvity, Inc. is set to present at the J.P. Morgan Healthcare Conference on January 13, 2026, with CEO Prahlad Singh sharing insights on the company's future. The event will be accessible via a live webcast, followed by a replay for stakeholders.

December 16, 2025 Revvity Inc. Launches Signals Xynthetica: A Game-Changer in AI-Augmented Molecular and Materials Discovery Revvity Inc. has launched Signals Xynthetica, an AI platform designed to enhance molecular and materials discovery by integrating predictive models into scientific workflows. This innovation bridges gaps in data and experimental validation, promising to accelerate discovery in various industries.

November 10, 2025 Revvity Inc. to Acquire ACD/Labs, Enhancing Scientific Software Solutions Revvity Inc. is set to acquire ACD/Labs to bolster its Signals software capabilities, integrating advanced analytical tools for pharmaceutical and chemical research. This strategic move aims to streamline workflows and enhance data-driven insights in the scientific community.

November 04, 2025 Revvity Inc. Reports 2025 Q3 Financial Results: Incremental Growth Amid Operational Changes Revvity Inc. reports a 2% revenue increase in Q3 2025, driven by its Diagnostics and Life Sciences segments. Despite rising costs, the company maintains a strong focus on innovation and cost management.

October 27, 2025 Revvity Inc. Reports Third Quarter Financial Results for 2025 Revvity Inc. reported Q3 2025 earnings with a decline in EPS to $0.40 despite a revenue increase to $699 million. The company is optimistic about future growth driven by innovations and strategic partnerships.

October 23, 2025 Revvity Inc. Declares Quarterly Dividend Amidst Strong Financial Performance Revvity Inc. has declared a quarterly dividend of $0.07 per share, reflecting its strong financial performance with revenues exceeding $2.7 billion. The company is positioned as a leader in health sciences, focusing on innovative solutions that enhance healthcare outcomes.

October 14, 2025 Revvity Inc. Highlights Sustainability Progress in 2025 Impact Report Revvity, Inc. has released its 2025 Impact Report, detailing significant advancements in sustainability, including a 6% reduction in emissions and a 49% waste diversion rate. The report highlights the company's educational initiatives and its recognition as a leader in environmental, social, and governance (ESG) practices.

October 06, 2025 Revvity Inc. Set to Release Q3 2025 Financial Results on October 27 Revvity, Inc. will release its Q3 2025 financial results on October 27, followed by an earnings call at 8:00 a.m. ET. The company continues to lead in health science innovations, with a strong focus on transparency and stakeholder engagement.

October 02, 2025 Revvity Inc. Announces Ambitious Program for Early Detection of Type 1 Diabetes Revvity, Inc. has announced a new initiative to enhance early detection of Type 1 Diabetes with its T1D 4-plex assay, developed in collaboration with Sanofi. This program aims to facilitate population-scale screening and improve health outcomes for millions globally. The partnership is set to bridge research and clinical application in diabetes diagnostics.

September 29, 2025 Revvity Inc. Launches Cutting-Edge AI Software to Revolutionize Preclinical Imaging Analysis Revvity Inc. has launched its Living Image Synergy AI software, an innovative tool designed to enhance preclinical imaging analysis by unifying data from various modalities. This software leverages AI to automate processes, streamline workflows, and improve reproducibility in research, set to debut at the WMIC conference.

September 22, 2025 Revvity Inc. Partners with Profluent to Advance AI-Enhanced Base Editing Technologies Revvity Inc. has partnered with Profluent to enhance gene editing through AI-driven technologies. Their collaboration focuses on the Pin-point™ platform, increasing precision and efficiency in therapeutic applications. This partnership aims to democratize access to advanced editing tools and accelerate the development of life-changing therapies.

August 05, 2025 Revvity Inc. Reports Steady Growth in Q2 2025 Financial Results Revvity Inc. reported $720.3 million in revenue for Q2 2025, a 4% increase year-over-year. The company noted growth in both Life Sciences and Diagnostics segments, despite rising costs. With strong liquidity and strategic investments, Revvity is poised for continued success.

May 06, 2025 Revvity Inc. Reports Steady Growth in Q1 2025 Financial Performance Revvity Inc. has announced a 2% revenue growth for Q1 2025, reaching $664.8 million, primarily fueled by its Diagnostics and Life Sciences segments. The company also reported improved net income and operational efficiency, highlighting its commitment to innovation and strategic partnerships in the health science sector.

April 30, 2025 Revvity Inc. to Showcase Strategic Insights at Upcoming Investor Conferences Revvity Inc. will present at two significant investor conferences in May and June 2025, showcasing its strategic initiatives and financial performance. Key executives will provide insights into the company's healthcare technology advancements and future growth prospects.

April 28, 2025 Revvity Inc. Reports Strong Financial Results for Q1 2025 Revvity, Inc. reported impressive Q1 2025 financial results, with a GAAP EPS of $0.35 and revenue of $665 million. The company has revised its full-year guidance, projecting growth amid economic challenges.

April 24, 2025 Revvity Inc. Declares Quarterly Dividend: A Positive Signal for Investors Revvity Inc. has declared a quarterly dividend of $0.07 per share, reflecting its robust financial position and commitment to shareholder value. With significant revenue growth and a diverse customer base, Revvity is well-positioned in the health tech industry, making it a promising investment opportunity.

April 03, 2025 Revvity Inc. Announces Upcoming Earnings Call for Q1 2025 Revvity Inc. will release its Q1 2025 financial results on April 28, followed by a conference call featuring leadership insights. The company, a leader in healthcare technology, aims to provide critical updates on its performance and strategic initiatives.

April 02, 2025 Revvity Inc. Secures FDA Approval for Advanced Tuberculosis Testing Solution Revvity, Inc. has received FDA approval for its Auto-Pure 2400 platform, designed to enhance TB testing efficiency and accuracy. This innovative system supports high-throughput testing, reducing processing time and improving patient outcomes in the fight against tuberculosis.

March 03, 2025 Revvity Inc. Launches CE-Marked Measles Antibody Detection Assay Revvity Inc. has launched the CE-marked Anti-Measles Virus ELISA 2.0 assay, improving measles diagnostics through innovative dried blood spot technology. This advancement aims to enhance global health outcomes by addressing the urgent need for effective measles testing.

February 25, 2025 SWOT Analysis of Revvity Inc. in 2025 This article provides a detailed SWOT analysis of Revvity Inc. in 2025, focusing on its strengths like brand loyalty and technological leadership, alongside weaknesses such as market dependence. It also explores opportunities for growth in high-demand markets and threats from competition and regulatory challenges.

February 25, 2025 Revvity Inc. Reports Steady Progress in 2024 Annual Financial Results Revvity Inc. has reported its 2024 annual financial results, revealing a modest revenue increase of $2.75 billion. While the Diagnostics segment thrived, the Life Sciences segment faced declines. The company continues to focus on strategic growth and innovation in health sciences.

February 20, 2025 Revvity Inc. Set to Showcase Innovations at Upcoming Investor Conferences Revvity Inc. will present at four major investor conferences in March 2025, offering insights into their strategic initiatives and healthcare innovations. The events will feature key executives and provide audio webcasts for those unable to attend.

February 20, 2025 Revvity Inc. Secures Permanent Injunction in Landmark Legal Victory Revvity Inc. achieved a significant legal victory with a Massachusetts Superior Court ruling that grants a permanent injunction for its Spotfire software agreements. This decision guarantees uninterrupted service for clients and strengthens Revvity's commitment to providing high-quality healthcare solutions. The ruling also solidifies Revvity's collaborative partnership with Cloud Software Group.

November 06, 2024 Revvity Inc. Reports Q3 2024 Financial Results: A Mixed Bag of Growth and Decline Revvity Inc. reported a revenue increase of 2% for Q3 2024, driven by growth in its Diagnostics segment, while facing declines in Life Sciences. The company continues to adapt to market challenges and remains focused on innovation and operational efficiency.

August 06, 2024 Revvity Inc. Reports Q2 2024 Financial Results: A Mixed Performance Amid Strategic Evolution Revvity Inc. reports a mixed financial performance for Q2 2024, with a slight revenue decline but improved net income. The company focuses on innovation and strategic initiatives amidst market challenges, maintaining a strong liquidity position.

May 07, 2024 Revvity Inc. Reports Q1 2024 Financial Results: A Mixed Bag Amid Strategic Evolution Revvity Inc. reported a 4% decline in revenue for Q1 2024, primarily due to challenges in its Life Sciences segment. Despite this, the company shows resilience in Diagnostics and is focused on strategic initiatives to drive future growth.

Revvity Inc. Prepares for Earnings Call with Positive Financial Update

Last updated: January 12, 2026 •

Taurigo

1. Key Earnings Call Scheduled for February 2, 2026

Revvity, Inc. (NYSE: RVTY) has officially announced a significant upcoming earnings call set for Monday, February 2, 2026. The company will reveal its financial performance for the fourth quarter and full year of 2025, with results being released prior to market opening on the same day. The call will commence at 8:00 a.m. ET, featuring prominent executives including Prahlad Singh, President and CEO, alongside Max Krakowiak, Chief Financial Officer.

Investors and analysts interested in the results can access the live audio webcast through the Investors section of Revvity’s website, ensuring transparency and real-time updates for stakeholders.

2. Preliminary Financial Performance

In anticipation of the earnings call, Revvity has provided preliminary financial results for the fourth quarter of 2025, showcasing a positive outlook. The company expects a reported revenue growth of approximately 6% and an organic growth of around 4% compared to the same period the previous year. This trend is anticipated to culminate in an estimated fourth-quarter revenue of approximately $772 million.

For the entire year of 2025, Revvity anticipates a reported revenue growth of about 4% and an organic growth of 3%, leading to a projected total revenue of around $2,855 million. This performance indicates steady growth, reflecting the company's resilience in a challenging economic environment.

In an encouraging sign for investors, Revvity also announced that its full-year adjusted earnings per share (EPS) are expected to exceed the upper end of the previously guided range of $4.90 to $5.00 provided on October 27, 2025. This positive revision suggests that the company has managed to navigate market conditions effectively while delivering solid financial outcomes.

3. Presentation at the J.P. Morgan Healthcare Conference

In addition to the earnings call, Prahlad Singh is scheduled to present at the prestigious 44th annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. PT. This event is a key platform for healthcare and biotech companies, where executives share insights and strategic directions. A live audio webcast of Singh's presentation will also be made available, alongside a slide presentation, further enhancing the accessibility of Revvity's corporate communications.

4. Conclusion

Revvity, Inc. is set to deliver an important financial update that reflects its growth trajectory and resilience. With positive preliminary results for the fourth quarter and full year of 2025, the upcoming earnings call is highly anticipated among investors. The presentations at the J.P. Morgan Healthcare Conference further solidify Revvity’s commitment to engaging with its stakeholders and maintaining transparency in its operations. As the company prepares for these key events, all eyes will be on its financial performance and strategic direction for the year ahead.

Original press release

You may also be interested in: